N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=77 Psychosis Screening in Juvenile Justice
Psychotic Disorders · Psychosis Nos/Other
Primary: Number of Participants Who Used Outpatient Mental Health Services — 20; 9 Participants — p=.053
Phase 3 N=323 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
N/A N=103 USS Training to Improve Social Function in People With Psychosis
Psychosis
Primary: Social Functioning Scale (SFS) Change — 1.28; 0.19; 1.56; 0.32 score on a scale
Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
N/A N=116 Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
Psychosis
Primary: Change in Generalized Anxiety Disorder-7 Pre/Post Test at Week 5 — 4.68; 6.28; 3.96; 7.38 units on a scale — p=0.003
N/A N=292 Early Detection and Intervention for the Prevention of Psychosis
Schizophrenia · Bipolar Disorder · Depression
Primary: Psychotic Symptoms — 9.2; 6.7 units on a scale — p=.0034
N/A N=124 Yoga and Aerobic Exercise in Psychosis
Psychotic Disorder
Primary: Verbal Acquisition — 22.8; 22.0; 22.7; 29.5 correctly encoded words — p=<0.01
Phase 2 N=39 A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
Parkinson Disease Psychosis
Primary: Change From Double Blind (DB) Baseline in Total Scale for Assessment of Positive Symptoms - Parkinson's Disease ( SAPS-PD) Score at Week 6 — -1.4; -2.5 Units on a scale
N/A N=50 Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
Attenuated Psychosis Syndrome
Primary: Brain Volume — 19.8; 54.8; -0.489; -6.28 Change in mm cubed (baseline -followup)
N/A N=60 iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders
Schizophrenia · Schizo Affective Disorder · Psychotic Disorders
Primary: Trained Introspective Accuracy — 3.70; -0.77 score on a scale — p=<0.001
Phase 2 N=90 Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
Parkinson's Disease · Psychotic Disorders
Primary: Patient Evaluation of Symptoms of Psychosis. — -9.8; -12.9; -9.7; -10.0 Scores on a scale — p=0.5177
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50
Phase 3 N=463 A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at Week 6 — -19.3; -16.9; -19.6 score on a scale — p=0.886
Phase 4 N=80 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale
Phase 3 N=8 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
Schizophreniform Disorder · Schizoaffective Disorder · Psychosis
Primary: Weight Gain and Other Side Effects
Phase 2 N=18 Cannabidiol Treatment in Patients With Early Psychosis
Schizophrenia · Schizoaffective Disorder
Primary: Positive and Negative Syndrome Scale (PANSS) Over Time — 81.3; 84.0; 78.3; 75.3 score on a scale — p=0.08
Phase 4 N=299 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale
Phase 3 N=228 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935
Phase 2 N=245 A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001
Phase 3 N=392 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Dementia-related Psychosis
Primary: Time From Randomization to Relapse in the Double-blind (DB) Period — NA; NA days — p=0.0023
Phase 3 N=97 Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -22.9; -19.4 Units on a scale — p=<0.0001
Phase 3 N=208 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Dementia, Alzheimer Type
Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 2 N=30 Diabetes in Neuropsychiatric Disorders
Schizophrenia
Primary: Body Mass Index — 22.1; 23.5; 24.2; 24.3 kg/m^2 — p=<0.001
Phase 2 N=56 A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
Schizophrenia
Primary: Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8 — 5.85; 7.28; 28.4; 12.1 ng/ml
N/A N=8 Clinical Interviews With Detainees With Early Psychosis
First-Episode Psychosis
Primary: Number of Referrals to Correctional Health Services (CHS) — 8 Participants
Phase 3 N=294 An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
Schizophrenia
Primary: Number of Participants With Treatment Response Based on Total PANSS Scale Score — 195 Participants